DUBLIN--(BUSINESS WIRE)--The "Polycystic Ovarian Syndrome - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape.
Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.
It provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Polycystic Ovarian Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Polycystic Ovarian Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycystic Ovarian Syndrome (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
1. Introduction
- Report Coverage
2. Polycystic Ovarian Syndrome - Overview
3. Polycystic Ovarian Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
4. Polycystic Ovarian Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
5. Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
- AbbVie Inc
- Arkay Therapeutics LLC
- Bayer AG
- BioRestorative Therapies Inc
- Cadila Healthcare Ltd
- EffRx Pharmaceuticals SA
- Jiangsu Hengrui Medicine Co Ltd
- KinDex Pharmaceuticals Inc
- Spruce Biosciences Inc
6. Polycystic Ovarian Syndrome - Drug Profiles
- (celecoxib + metformin hydrochloride + valsartan) - Drug Profile
- Drug for Polycystic Ovarian Syndrome - Drug Profile
- elagolix sodium - Drug Profile
- KDT-501 - Drug Profile
- metformin hydrochloride - Drug Profile
- Recombinant Protein to Agonize PEDF for Women's Health - Drug Profile
- saroglitazar - Drug Profile
- SHR-7280 - Drug Profile
- Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
- ThermoStem - Drug Profile
- tildacerfont - Drug Profile
7. Polycystic Ovarian Syndrome - Dormant Projects
8. Polycystic Ovarian Syndrome - Discontinued Products
9. Polycystic Ovarian Syndrome - Product Development Milestones
- Featured News & Press Releases
- Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
- Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations
10. Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
Companies Mentioned
- AbbVie Inc
- Arkay Therapeutics LLC
- Bayer AG
- BioRestorative Therapies Inc
- Cadila Healthcare Ltd
- EffRx Pharmaceuticals SA
- Jiangsu Hengrui Medicine Co Ltd
- KinDex Pharmaceuticals Inc
- Spruce Biosciences Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fp8has
